University of Alabama researchers have retracted a paper claiming that a grape skin seed compound might have anti-prostate cancer effects.
Here’s the notice for “Proanthocyanidins from grape seeds inhibit expression of matrix metalloproteinases in human prostate carcinoma cells, which is associated with the inhibition of activation of MAPK and NFκB”: Continue reading Authors retract prostate cancer-grape seed compound paper for figure presentation error
Laurence Klotz, a prominent urologist at the University of Toronto who studies the prostate specific antigen (PSA), has corrected a paper after reusing his own words from an earlier review.
Here’s the correction, from the Journal of Clinical Oncology (JCO): Continue reading Duplication earns highly cited prostate cancer researcher a correction in JCO
Anil Potti, the former Duke cancer researcher who has now retracted or corrected 18 papers amidst investigations into his work, is now working at a Grand Forks, North Dakota, cancer center.
The Grand Forks Herald reports that Potti has worked at the Cancer Center of North Dakota since May. His new boss, William Noyes, told the paper that Continue reading Anil Potti resurfaces with job at North Dakota cancer center
The European Journal of Surgical Oncology has retracted a meeting abstract that evidently was never meant to be.
The study, by researchers at Queen Elizabeth Hospital and Good Hope Hospital, both in Birmingham, England, was to be presented at this year’s annual meeting of the Association of Breast Surgery and purported to compare rates of patient satisfaction among women who underwent two kinds of breast reconstruction, TRAM — transverse rectus abdominis myocutaneous — flap and DIEP (short for deep inferior epigastric perforators) flap.
But according to the notice: Continue reading Cancer journal pulls deeply flawed meeting abstract on breast surgery
Robert Getzenberg, the Johns Hopkins prostate cancer researcher who has recently retracted two papers involved in work he was sued over, has left the university, Retraction Watch has learned.
Getzenberg, who directed the Research Laboratories at the Hopkins’ Brady Urological Institute, has been working on an alternative to the prostate-specific antigen (PSA) test. In 2009, he — along with Hopkins and Pitt, his former employer — was sued by a company that funded his work, Science magazine reported at the time. The suits were eventually settled for an undisclosed amount, and Getzenberg and his colleagues have now retracted two papers, one in Urology and one in The Prostate, as we’ve reported. Continue reading Prostate cancer researcher who retracted two studies at center of lawsuit departs Hopkins
Expert Opinion on Pharmacotherapy has retracted a 2011 paper for plagiarism by two authors, one of whom, V. Craig Jordan, is a leading researcher on the class of drugs known as selective estrogen receptor modulators, or SERMs, and is credited with discovering the anti-tumor properties of the breast cancer drug tamoxifen.
Jordan, who is scientific director at the Lombardi Comprehensive Cancer Center at Georgetown University, appears to have been unaware of the offense when the paper was published. Here’s the notice: Continue reading Plagiarism topples paper co-authored by top tamoxifen scientist
Earlier this year, we reported on the case of Robert Getzenberg of Johns Hopkins, who retracted a 2007 paper in Urology that was “at the center of two 2009 lawsuits brought by a company that funded the work.”
Getzenberg has now retracted a related paper, “Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2,” published in The Prostate in 2009 and cited nine times, according to Thomson Scientific’s Web of Knowledge.
The notice in The Prostate goes further than the one in Urology, using the word “falsification:” Continue reading Another retraction for potential prostate cancer test from Hopkins
An unusual note went out to reporters on the Journal of the National Cancer Institute (JNCI) press list yesterday:
Please disregard this MTM, which was sent out on Friday June 29, 2012. The data in the study changed so we are no longer putting out a press release for the study.
The original release was headlined:
Percent Density May Be As Strong a Risk Factor as Variation in Breast Density for Breast Cancer
MTM stands for “memo to the media.” What wasn’t clear was whether the new notice meant the release was being pulled back, or the study itself, but the JNCI press office said it was just the release.
But the Mayo Clinic’s Celine Vachon told Retraction Watch: Continue reading Confusion as JNCI yanks press release on embargoed breast density-cancer study after authors see error
One of the biggest stories so far out of the American Society of Clinical Oncology (ASCO) meeting that just ended in Chicago was that of T-DM1, which, according to Ivan’s Reuters colleagues, “extended the length of time breast cancer patients lived without their disease getting worse.” (The news was even the subject of an embargo break.)
The widely-hailed study of Roche’s drug was led by Duke’s Kimberly Blackwell, who told The New York Times: Continue reading Lead author of major breast cancer study announced at ASCO co-authored two corrected papers with Anil Potti
Gerold Schuler, a German immunology researcher who shared the 2006 Deutscher Krebspreis — aka the German Cancer Prize — for his work that contributed to cancer vaccines has retracted a paper in International Immunology following concerns raised by a German science watchdog blog.
Here’s the notice: Continue reading Leading cancer vaccines researcher retracts paper for figure “discrepancies” flagged by watchdog blog